Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Pembrolizumab
Treatment for Cervical cancer
Typical Dosage: 200 mg IV every 3 weeks or 400 mg IV every 6 weeks
Effectiveness
45%
Safety Score
40%
Clinical Trials
457
Participants
3K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
40
DangerousModerateSafe
Treatment Details
Dosage Range
200 mg IV every 3 weeks or 400 mg IV every 6 weeks
Time to Effect
Weeks to months
Treatment Duration
Until progression or up to 2 years
Evidence Quality
HIGHNumber Needed to Treat (NNT)
8(Treat 8 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
15(Treat 15 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$180,000
Monitoring:$10,000
Side Effect Mgmt:$5,000
Total Annual:$195,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$350,000/QALY
QALYs Gained
0.6
Outcome-Based Costs
Cost per Responder
$780,000
Comparison vs Chemotherapy (e.g., Cisplatin/Paclitaxel)
Cost Difference
+$140,000/year
More expensive
QALY Difference
+0.30 QALYs
Better outcomes
Dominance
No dominance
Pembrolizumab Outcomes
for Cervical cancer
Efficacy Outcomes
Overall Effectiveness
+45%
Response Rate
+25%
Remission Rate
+3%
Common Side Effects
Fatigue
+45%
Nausea
+25%
Diarrhea
+20%
Rash
+18%
Pruritus
+12%
Immune-related adverse events
+10%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
7 active trials recruiting for Pembrolizumab in Cervical cancer
Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia
NCT04712851RECRUITINGPHASE2
25 participants
INTERVENTIONAL
Los Angeles, United States
Started: Jun 30, 2021
GYNecological Cancers Treated with NETrin MAbs in Combination with Chemotherapy and /or Pembrolizumab
NCT04652076ACTIVE NOT RECRUITINGPHASE1, PHASE2
240 participants
INTERVENTIONAL
Besançon, France +14 more
Started: Dec 14, 2020
Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)
NCT06266338RECRUITINGPHASE2
30 participants
INTERVENTIONAL
Dallas, United States
Started: Mar 11, 2024
Pembrolizumab Concurrent With and Following Carbon-ion Radiotherapy for Locally Advanced Cervical Adenocarcinoma
NCT06805864NOT YET RECRUITINGPHASE2
45 participants
INTERVENTIONAL
Maebashi, Japan
Started: Feb 1, 2025
Pembrolizumab and Lenvatinib in Advanced Cervical Cancer
NCT04865887RECRUITINGPHASE2
35 participants
INTERVENTIONAL
Washington D.C., United States +3 more
Started: Oct 7, 2022
PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
NCT06157151RECRUITINGPHASE2
24 participants
INTERVENTIONAL
Little Rock, United States +2 more
Started: Nov 11, 2025
The Efficacy of Lymph Node Dissection for Stage IIICr of Cervical Cancer(CQGOG0103)
NCT04555226RECRUITINGNA
452 participants
INTERVENTIONAL
Chongqing, China
Started: Jan 11, 2021
Completed Clinical Trials
6 completed trials for Pembrolizumab in Cervical cancer
The Combination of GX-188E Vaccination and Pembrolizumab in Patients With HPV 16 and/or 18+ Advanced Cervical Cancer
NCT03444376COMPLETEDPHASE1, PHASE2
65 participants
INTERVENTIONAL
Busan, South Korea +8 more
Started: Jun 19, 2018
Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)
NCT04221945COMPLETEDPHASE3
1.06K participants
INTERVENTIONAL
Phoenix, United States +175 more
Started: May 12, 2020
Pembrolizumab and Chemoradiation Treatment for Advanced Cervical Cancer
NCT02635360COMPLETEDPHASE2
94 participants
INTERVENTIONAL
Mobile, United States +7 more
Started: Feb 9, 2017
Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)
NCT03635567COMPLETEDPHASE3
617 participants
INTERVENTIONAL
Anchorage, United States +148 more
Started: Oct 25, 2018
Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck
NCT02289209COMPLETEDPHASE2
48 participants
INTERVENTIONAL
Baltimore, United States +3 more
Started: Mar 9, 2016
A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001)
NCT06894771COMPLETEDPHASE1
5 participants
INTERVENTIONAL
Hackensack, United States +6 more
Started: Apr 23, 2025
Showing 20 of 476 total trials